CYRX Reddit Mentions | ChartExchange

# Sony ($SONY): The perception play for the physical AI era
Most investors are stuck on the brain of AI like Nvidia or LLMs, but I think Sony is the ultimate pick and shovel play for the next 5 to 10 years. We are hitting a hardware bottleneck for physical AI: if a robot or car is going to move in the real world, it needs eyes. Sony dominates over 50 percent of the image sensor market and is shifting from simple smartphone sensors to edge computing with on-chip AI logic.
New sensors like the IMX735 allow for instant processing at the source, which is mandatory for avoiding the latency of the cloud in robotics. Recent leaks show Tesla moving toward Sony for the AI5 suite, and Boston Dynamics is already a heavy user of their high-speed sensors.
The music and pictures divisions are massive cash cows that provide a floor while the semiconductor division scales into the trillion-dollar robotics market. Trading at a pe of 15, it is an undervalued play hiding in plain sight.
# Siltronic ($WAF): The essential wafer turnaround
No matter who wins the chip wars, they all need wafers. Siltronic is the top-tier (and only) European provider and is currently a classic worst-behind-us turnaround story. While they are navigating some near-term sales dips, they are doubling down on 300mm wafer production at their Singapore site.
As the cycle turns and AI chips demand more specialized substrates, Siltronic is perfectly positioned to capture the expansion of the hardware layer.
# Samsung SDI ($SSDIY): The data center and non-CATL power play
Samsung SDI is becoming the go-to premium battery alternative for Western manufacturers who want to avoid or diversify away from Chinese battery manufacturers. They are finalizing a deal worth up to 1 billion dollars with Amazon/AWS to provide battery backup units for data centers. These systems are critical for maintaining uptime during the massive power surges required by AI workloads. Beyond data centers, they have locked-in deals with carmakers such as Mercedes and Stellantis, and I believe they may benefit from the massive net income by the parent company, which may want to double down on their subsidiaries as to not put all their eggs in one basket incase memory does become somewhat cyclical again.
# SAP & Secunet: The EU digital and security backbone
SAP is far from dead; it is the sovereign cloud play for Europe. With their new AI assistant Joule and the shift to S/4HANA, they have a massive recurring revenue moat that businesses cannot simply switch off.
Secunet is the cybersecurity partner of the German government. Their order intake just rose over 90 percent to 143 million euros, driven by defense, space, and European border control systems. It is a niche, high-barrier play that is essential for regional security.
# ams OSRAM ($AMS): Optical data transfer and smart glasses
Overlooked and hated by analysts, ams OSRAM is shifting toward digital photonics. They are exploring micro-emitter array-based optical interconnects for AI data centers to allow for massive, parallel data transfer with low power consumption. With their tech also being built into next-gen smart glasses, they are on a path to positive free cash flow next year.
# WaterBridge Infrastructure: The Delaware Basin utility
This is a pure infrastructure play on the energy sector. For every barrel of oil produced in the Delaware Basin, you get 4 to 10 barrels of dirty produced water. WaterBridge handles over 2.5 million barrels of this water every day. Their moat is the physical pipe network—transporting water via pipe is significantly cheaper and more regulated than using trucks. They only take on projects with ultra-fast paybacks, creating a toll-road business model that is essential for the basin to function, especially with oil prices where the are, the Permian basin will continue to thrive.
# Cryoport ($CYRX): The cold chain for CGT and IVF
Cryoport has an fda regulatory moat because their systems are built into the actual filings for cell and gene therapies (CGT). You cannot just swap out a logistics provider for a 500,000 dollar therapy without risking regulatory delays. They now support 766 clinical trials and 21 commercial therapies. By offloading their specialty courier to DHL, they have pivoted to a high-margin platform model. Furthermore, global fertility rates are trending down, making egg and embryo preservation through their Cryostork business a major, non-cyclical growth driver for the next decade.
Some of my other strong bets, which pop up way too often though: Amazon / Microsoft / JD.com. I am also holding Centene and UNH from the previous panic but am not adding more at these levels. Other non core positions include constellation brands, UPS, target, General Mills, novo nordisk, Lyft, PayPal and universal music.
Disclaimer: Not financial advice.